ICP-332 Compared With Placebo for Moderate to Severe Plaque Psoriasis
Compares ICP-332 tablets with placebo tablets in adults with moderate to severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07251998, who can take part
Where in China
- Shanghai Dermatology HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing InnoCare Pharma Tech Co., Ltd.
- Trial code
- NCT07251998
- Record updated
- 31 December 2025
- Original description
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.Read full original descriptionShow less
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-332 in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Inclusion: Subjects voluntarily participate in this study and have signed the Informed Consent Form (ICF); Male or female subjects aged ≥ 18 years and ≤ 70 years; A history of plaque psoriasis for ≥6 months at baseline; Meet the following three criteria:; Psoriasis Area and Severity Index (PASI) score ≥12; Static Physician's Global Assessment (sPGA) score ≥3; Psoriasis affected Body Surface Area (BSA) ≥10%; The subject requires systemic treatment and/or phototherapy.
Exclusion: Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization); Presence of clinically serious, progressive, or uncontrolled disease; Subject had laboratory values meeting any of the protocol-specified criteria at Screening; Diagnosed with non-plaque psoriasis; Pregnant or lactating women; The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.